Active Ingredient History
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration, diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Angioid Streaks (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2/Phase 3)
Cardiovascular Diseases (Phase 1/Phase 2)
Cataract (Phase 4)
Central Serous Chorioretinopathy (Phase 1/Phase 2)
Cerebrovascular Disorders (Phase 4)
Choroidal Neovascularization (Phase 4)
Choroiditis (Phase 1/Phase 2)
Conjunctival Neoplasms (Phase 1)
Corneal Neovascularization (Phase 1)
Coronary Artery Disease (Phase 4)
Depression (Phase 1)
Diabetes Complications (Phase 2/Phase 3)
Diabetes Mellitus (Phase 4)
Diabetic Angiopathies (Phase 1/Phase 2)
Dyslipidemias (Phase 1/Phase 2)
Endothelium (Phase 4)
Epistaxis (Phase 1)
Eye Diseases (Phase 3)
Glaucoma (Phase 3)
Glaucoma, Neovascular (Phase 4)
Glaucoma, Open-Angle (Phase 1)
Hemorrhage (Phase 1)
Ischemia (Phase 4)
Livedoid Vasculopathy (Phase 4)
Macula Lutea (Phase 4)
Macular Degeneration (Phase 4)
Melanoma (Phase 4)
Membranes (Phase 1/Phase 2)
Myopia, Degenerative (Phase 3)
Nasal Cavity (Phase 1)
Neovascularization, Pathologic (Phase 4)
Neurofibroma (Early Phase 1)
Neurofibromatosis 1 (Early Phase 1)
Ophthalmology (Phase 2/Phase 3)
Optic Neuropathy, Ischemic (Phase 1)
Pathologic Processes (Phase 1)
Port-Wine Stain (Phase 1)
Pseudoxanthoma Elasticum (Phase 1/Phase 2)
Pterygium (Phase 2/Phase 3)
Ranibizumab (Phase 4)
Retinal Degeneration (Phase 2)
Retinal Detachment (Phase 4)
Retinal Diseases (Phase 4)
Retinal Dystrophies (Phase 2)
Retinal Hemorrhage (Phase 2/Phase 3)
Retinal Neovascularization (Phase 2)
Retinal Perforations (Phase 2)
Retinal Telangiectasis (Phase 1/Phase 2)
Retinal Vein Occlusion (Phase 4)
Retinoblastoma (Phase 2)
Retinopathy of Prematurity (Phase 3)
Stargardt Disease (Phase 1/Phase 2)
Telangiectasis (Phase 2)
Therapeutics (Phase 4)
Trabeculectomy (Phase 1)
Uveitis (Phase 3)
Vascular Diseases (Phase 1/Phase 2)
Vision Disorders (Phase 4)
Vision, Ocular (Phase 2)
Visual Acuity (Phase 4)
Visual Pathways (Phase 4)
Vitreous Body (Phase 1)
Vitreous Detachment (Phase 2)
Vitreous Hemorrhage (Phase 4)
von Hippel-Lindau Disease (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
